Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects APPLICATIONS TO BISPECIFIC MOLECULES AND MONOVALENT IgG

被引:225
作者
Gunasekaran, Kannan [1 ]
Pentony, Martin [1 ]
Shen, Min [1 ]
Garrett, Logan [1 ]
Forte, Carla [1 ]
Woodward, Anne [1 ]
Bin Ng, Soo [2 ]
Born, Teresa [2 ]
Retter, Marc [3 ]
Manchulenko, Kathy [4 ]
Sweet, Heather [4 ]
Foltz, Ian N. [4 ]
Wittekind, Michael [1 ]
Yan, Wei [1 ]
机构
[1] Amgen Inc, Dept Prot Sci, Seattle, WA 98119 USA
[2] Amgen Inc, Dept Inflammat, Seattle, WA 98119 USA
[3] Amgen Inc, Dept Pharmacokinet & Drug Metab, Seattle, WA 98119 USA
[4] Amgen British Columbia, Burnaby, BC V5A 1V7, Canada
关键词
PROTEIN-PROTEIN INTERACTIONS; COILED-COIL; CONSTANT DOMAINS; IN-VIVO; DESIGN; FRAGMENT; IDENTIFICATION; THERAPEUTICS; ASSOCIATION; INTERFACE;
D O I
10.1074/jbc.M110.117382
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Naturally occurring IgG antibodies are bivalent and monospecific. Bispecific antibodies having binding specificities for two different antigens can be produced using recombinant technologies and are projected to have broad clinical applications. However, co-expression of multiple light and heavy chains often leads to contaminants and pose purification challenges. In this work, we have modified the CH3 domain interface of the antibody Fc region with selected mutations so that the engineered Fc proteins preferentially form heterodimers. These novel mutations create altered charge polarity across the Fc dimer interface such that coexpression of electrostatically matched Fc chains support favorable attractive interactions thereby promoting desired Fc heterodimer formation, whereas unfavorable repulsive charge interactions suppress unwanted Fc homodimer formation. This new Fc heterodimer format was used to produce bispecific single chain antibody fusions and monovalent IgGs with minimal homodimer contaminants. The strategy proposed here demonstrates the feasibility of robust production of novel Fc-based heterodimeric molecules and hence broadens the scope of bispecific molecules for therapeutic applications.
引用
收藏
页码:19637 / 19646
页数:10
相关论文
共 33 条
[1]
Comparison of in vivo selection and rational design of heterodimeric coiled coils [J].
Arndt, KM ;
Pelletier, JN ;
Müller, KM ;
Plückthun, A ;
Alber, T .
STRUCTURE, 2002, 10 (09) :1235-1248
[2]
A heterodimeric coiled-coil peptide pair selected in vivo from a designed library-versus-library ensemble [J].
Arndt, KM ;
Pelletier, JN ;
Müller, KM ;
Alber, T ;
Michnick, SW ;
Plückthun, A .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 295 (03) :627-639
[3]
Helix-stabilized Fv (hsFv) antibody fragments:: Substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain [J].
Arndt, KM ;
Müller, KM ;
Plückthun, A .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 312 (01) :221-228
[4]
Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library [J].
Atwell, S ;
Ridgway, JBB ;
Wells, JA ;
Carter, P .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 270 (01) :26-35
[5]
BERNSTEIN FC, 1977, J MOL BIOL, V112, P542
[6]
Anatomy of hot spots in protein interfaces [J].
Bogan, AA ;
Thorn, KS .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 280 (01) :1-9
[7]
Bispecific human IgG by design [J].
Carter, P .
JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 248 (1-2) :7-15
[8]
Potent antibody therapeutics by design [J].
Carter, PJ .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (05) :343-357
[10]
Monomeric Fc fusions - Impact on pharmacokinetic and biological activity of protein therapeutics [J].
Dumont, Jennifer A. ;
Low, Susan C. ;
Peters, Robert T. ;
Bitonti, Alan J. .
BIODRUGS, 2006, 20 (03) :151-160